Genitope: Patient-specific manufacturing By Kathryn Calkins
Staff Writer

One major stumbling block to the promise of personalized medicines is manufacturing, which by definition produces high volumes of identical product over and over. Genitope Corp., which plans to commercialize a protein therapy specific to individual lymphoma patients, has created a manufacturing process that allows the company to turn genetic information from each patient's tumor into an immune stimulant directed specifically against the malignancy.